Abbott Laboratories (ABT)

Abbott is preparing to spin off its Nutrition business, which generates approximately $8.5 billion in annual sales, while retaining medical devices, diagnostics, and pharmaceuticals. Recent results showed $13 billion in third-quarter salesand adjusted EPS of $1.42, but analyst signals remain mixed as earnings estimates have edged lower. The stock was down 0.43% in the regular session on October 28, 2026.